LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.

Zhang, Ling / Pakmehr, Seyed Abbas / Shahhosseini, Reza / Hariri, Maryam / Fakhrioliaei, Azadeh / Karkon Shayan, Farid / Xiang, Wenxue / Karkon Shayan, Sepideh

Medical oncology (Northwood, London, England)

2023 Volume 41, Issue 1, Page(s) 8

Abstract: Immunotherapies using immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy have achieved successful results against several types of human tumors, particularly hematological malignancies. However, their clinical results ... ...

Abstract	Immunotherapies using immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy have achieved successful results against several types of human tumors, particularly hematological malignancies. However, their clinical results for the treatment of solid tumors remain poor and unsatisfactory. The immunosuppressive tumor microenvironment (TME) plays an important role by interfering with intratumoral T-cell infiltration, promoting effector T-cell exhaustion, upregulating inhibitory molecules, inducing hypoxia, and so on. Oncolytic viruses are an encouraging biocarrier that could be used in both natural and genetically engineered platforms to induce oncolysis in a targeted manner. Oncolytic virotherapy (OV) contributes to the reprogramming of the TME, thus synergizing the functional effects of current ICIs and CAR T-cell therapy to overcome resistant barriers in solid tumors. Here, we summarize the TME-related inhibitory factors affecting the therapeutic outcomes of ICIs and CAR T cells and discuss the potential of OV-based approaches to alleviate these barriers and improve future therapies for advanced solid tumors.
MeSH term(s)	Humans ; Oncolytic Viruses ; Receptors, Chimeric Antigen ; Tumor Microenvironment ; Immunotherapy, Adoptive/methods ; Immunotherapy/methods ; Neoplasms/pathology ; Oncolytic Virotherapy/methods
Chemical Substances	Receptors, Chimeric Antigen
Language	English
Publishing date	2023-12-08
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1201189-7
ISSN	1559-131X ; 0736-0118 ; 1357-0560
ISSN (online)	1559-131X
ISSN	0736-0118 ; 1357-0560
DOI	10.1007/s12032-023-02233-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1899: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives.

Soroush, Alborz / Pourhossein, Siavash / Hosseingholizadeh, Dorrin / Hjazi, Ahmed / Shahhosseini, Reza / Kavoosi, Haniyeh / Kermanshahi, Nazgol / Behnamrad, Parisa / Ghavamikia, Nima / Dadashpour, Mehdi / Karkon Shayan, Sepideh

Medical oncology (Northwood, London, England)

2024 Volume 41, Issue 5, Page(s) 125

Abstract: Plant-derived immunomodulators and antitumor factors have appealed lots of attention from natural product scientists for their efficiency and safety and their important contribution to well-designed targeted drug action and delivery mechanisms. Zerumbone ...

Abstract	Plant-derived immunomodulators and antitumor factors have appealed lots of attention from natural product scientists for their efficiency and safety and their important contribution to well-designed targeted drug action and delivery mechanisms. Zerumbone (ZER), the chief component of Zingiber zerumbet rhizomes, has been examined for its wide-spectrum in the treatment of multi-targeted diseases. The rhizomes have been used as food flavoring agents in numerous cuisines and in flora medication. Numerous in vivo and in vitro experiments have prepared confirmation of ZER as a potent immunomodulator as well as a potential anti-tumor agent. This review is an interesting compilation of all the important results of the research carried out to date to investigate the immunomodulatory and anticancer properties of ZER. The ultimate goal of this comprehensive review is to supply updated information and a crucial evaluation on ZER, including its chemistry and immunomodulating and antitumour properties, which may be of principal importance to supply a novel pathway for subsequent investigation to discover new agents to treat cancers and immune-related sickness. In addition, updated information on the toxicology of ZER has been summarized to support its safety profile.
MeSH term(s)	Animals ; Humans ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents, Phytogenic/therapeutic use ; Antineoplastic Agents, Phytogenic/pharmacology ; Glioma/drug therapy ; Neoplasms/drug therapy ; Sesquiterpenes/therapeutic use ; Sesquiterpenes/pharmacology ; Zingiberaceae/chemistry
Language	English
Publishing date	2024-04-23
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1201189-7
ISSN	1559-131X ; 0736-0118 ; 1357-0560
ISSN (online)	1559-131X
ISSN	0736-0118 ; 1357-0560
DOI	10.1007/s12032-024-02327-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1899: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Merkel cell carcinoma on the right calf in association with chronic lymphocytic leukemia: A case report.

Mohammadzadeh, Hamideh / Babaniamansour, Sepideh / Majidi, Mohammadreza / Zare, Abolfazl / Dehghani Firouzabadi, Mohammad / Karkon-Shayan, Sepideh

Clinical case reports

2021 Volume 9, Issue 7, Page(s) e04498

Abstract: This study showed a rare case of Merkel cell carcinoma (MCC) with atypical manifestations accompanied by chronic lymphocytic leukemia of B-cell type that underwent chemotherapy and had poor prognosis. The findings suggest that the physicians should ... ...

Abstract	This study showed a rare case of Merkel cell carcinoma (MCC) with atypical manifestations accompanied by chronic lymphocytic leukemia of B-cell type that underwent chemotherapy and had poor prognosis. The findings suggest that the physicians should consider MCC when performing diagnosis and assess all possible associated risk factors like neoplasms to achieve good prognosis.
Language	English
Publishing date	2021-07-06
Publishing country	England
Document type	Case Reports
ZDB-ID	2740234-4
ISSN	2050-0904
ISSN	2050-0904
DOI	10.1002/ccr3.4498
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Turmeric for Treatment of Irritable Bowel Syndrome: A Systematic Review of Population-Based Evidence.

Jafarzadeh, Emad / Shoeibi, Shahram / Bahramvand, Yaser / Nasrollahi, Elham / Maghsoudi, Armin Salek / Yazdi, Fatemeh / KarkonShayan, Sepideh / Hassani, Shokoufeh

Iranian journal of public health

2022 Volume 51, Issue 6, Page(s) 1223–1231

Abstract: Background: Irritable bowel syndrome (IBS) is a highly prevalent disorder of the gut interaction characterized by abdominal discomfort and pain associated with altered bowel habits in the absence of structural abnormalities. In spite of IBS' high ... ...

Abstract	Background: Irritable bowel syndrome (IBS) is a highly prevalent disorder of the gut interaction characterized by abdominal discomfort and pain associated with altered bowel habits in the absence of structural abnormalities. In spite of IBS' high prevalence and disease burden across the globe, no explanations have been given as to its underlying pathophysiology. As for the treatment of IBS, there is no specific medication, and the most beneficial treatment is usually supportive therapy. Recent animal and human studies have demonstrated the therapeutic potential of curcumin or turmeric in the treatment of IBS. Methods: We systematically reviewed all available evidence supporting curcumin and turmeric's therapeutic potential in relieving IBS symptoms in the present study. For this purpose, a database search was performed using curcumin, turmeric, and IBS and all their equivalents as of the search terms in Web of Science, Pub-Med, Scopus, Ovid, Embase, and Google Scholar from1990 up to Feb 2021. The investigation was then limited to clinical trials, and then nine articles were collected for data analysis. Results: The findings of the included literature showed that curcumin and turmeric alone or in combination with other medications could improve the severity of IBS as well as the quality of life among people who suffer from IBS symptoms. Conclusion: Overall, medications containing curcumin and turmeric extract due to these compounds' anti-inflammatory effects may improve IBS symptoms, particularly abdominal pain and life quality.
Language	English
Publishing date	2022-11-24
Publishing country	Iran
Document type	Journal Article ; Review
ZDB-ID	2240935-X
ISSN	2251-6093 ; 2251-6093
ISSN (online)	2251-6093
ISSN	2251-6093
DOI	10.18502/ijph.v51i6.9656
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Resveratrol as an antitumor agent for glioblastoma multiforme: Targeting resistance and promoting apoptotic cell deaths.

Karkon-Shayan, Sepideh / Aliashrafzadeh, Hasan / Dianat-Moghadam, Hassan / Rastegar-Pouyani, Nima / Majidi, Mohammadreza / Zarei, Mahdi / Moradi-Vastegani, Sadegh / Bahramvand, Yaser / Babaniamansour, Sepideh / Jafarzadeh, Emad

Acta histochemica

2023 Volume 125, Issue 6, Page(s) 152058

Abstract: Glioblastoma multiforme (GBM) is one of the most aggressive brain and spinal cord tumors. Despite the significant development in application of antitumor drugs, no significant increases have been observed in the survival rates of patients with GBM, as ... ...

Abstract	Glioblastoma multiforme (GBM) is one of the most aggressive brain and spinal cord tumors. Despite the significant development in application of antitumor drugs, no significant increases have been observed in the survival rates of patients with GBM, as GBM cells acquire resistance to conventional anticancer therapeutic agents. Multiple studies have revealed that PI3K/Akt, MAPK, Nanog, STAT 3, and Wnt signaling pathways are involved in GBM progression and invasion. Besides, biological processes such as anti-apoptosis, autophagy, angiogenesis, and stemness promote GBM malignancy. Resveratrol (RESV) is a non-flavonoid polyphenol with high antitumor activity, the potential of which, regulating signaling pathways involved in cancer malignancy, have been demonstrated by many studies. Herein, we present the potential of RESV in both single and combination therapy- targeting various signaling pathways- which induce apoptotic cell death, re-sensitize cancer cells to radiotherapy, and induce chemo-sensitizing effects to eventually inhibit GBM progression.
MeSH term(s)	Humans ; Glioblastoma/metabolism ; Resveratrol/pharmacology ; Phosphatidylinositol 3-Kinases/metabolism ; Brain Neoplasms/drug therapy ; Brain Neoplasms/metabolism ; Brain Neoplasms/pathology ; Antineoplastic Agents/pharmacology ; Apoptosis ; Cell Line, Tumor
Chemical Substances	Resveratrol (Q369O8926L) ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; Antineoplastic Agents
Language	English
Publishing date	2023-06-17
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	77-2
ISSN	1618-0372 ; 0065-1281
ISSN (online)	1618-0372
ISSN	0065-1281
DOI	10.1016/j.acthis.2023.152058
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ub I Zs.185: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Using Ozone Therapy as an Option for Treatment of COVID-19 Patients: A Scoping Review.

Radvar, Sarvin / Karkon-Shayan, Sepideh / Motamed-Sanaye, Ali / Majidi, Mohammadreza / Hajebrahimi, Sakineh / Taleschian-Tabrizi, Negar / Pashazadeh, Fariba / Sahebkar, Amirhossein

Advances in experimental medicine and biology

2021 Volume 1327, Page(s) 151–160

Abstract: Recent investigations are seeking a novel treatment to control the new pandemic of coronavirus 19 (COVID-19). The aim of this systematic review was to study the effect of ozone therapy on COVID-19 patients and the available supporting evidence. ... ...

Abstract	Recent investigations are seeking a novel treatment to control the new pandemic of coronavirus 19 (COVID-19). The aim of this systematic review was to study the effect of ozone therapy on COVID-19 patients and the available supporting evidence. Electronic databases including MEDLINE (via PubMed), EMBASE, Cochrane Library (CENTRAL), and TRIP, clinical trial registries, and preprint sources were searched for published evidence-based articles. In addition, manual searching was conducted for articles published up to April 6, 2020, using MeSH and free text keywords with no language limitation. Articles were screened, categorized, and extracted for relative data. Data were reported in a descriptive manner. Among 234 articles, 9 were selected for review of the inclusion criteria. No published original articles were found regarding the efficacy of ozone therapy on COVID-19. Five review studies were found in which the potential role of systemic ozone therapy was concluded to be effective in controlling COVID-19 because of its antiviral, oxygenation, anti-inflammatory, oxidation balancing, and immunomodulation effects. Three ongoing clinical trials were registered in China. A preliminary report of an ongoing study in Italy on 46 patients (11 intubated and 35 non-intubated) showed that in 39 (84%) of the patients, an improvement was seen. In spite of the promising background data, as well as the expert opinions and a preliminary report indicating the effectiveness of ozone, there is still not enough evidence to confirm this as a viable treatment option for COVID-19.
MeSH term(s)	COVID-19 ; China ; Humans ; Italy ; Ozone/therapeutic use ; SARS-CoV-2
Chemical Substances	Ozone (66H7ZZK23N)
Language	English
Publishing date	2021-07-19
Publishing country	United States
Document type	Journal Article ; Systematic Review
ISSN	2214-8019 ; 0065-2598
ISSN (online)	2214-8019
ISSN	0065-2598
DOI	10.1007/978-3-030-71697-4_12
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer.

Azani, Alireza / Omran, Sima Parvizi / Ghasrsaz, Haniyeh / Idani, Asra / Eliaderani, Mahdis Kadkhodaei / Peirovi, Niloufar / Dokhani, Negar / Lotfalizadeh, Mohamad Hassan / Rezaei, Mohammadhadi Mohammadzadeh / Ghahfarokhi, Mehrnoosh Shahgholian / KarkonShayan, Sepideh / Hanjani, Parisa Najari / Kardaan, Zahra / Navashenagh, Jamshid Gholizadeh / Yousefi, Meysam / Abdolahi, Mitra / Salmaninejad, Arash

Pathology, research and practice

2023 Volume 248, Page(s) 154618

Abstract: Globally, prostate cancer (PC) is leading cause of cancer-related mortality in men worldwide. Despite significant advances in the treatment and management of this disease, the cure rates for PC remains low, largely due to late detection. PC detection is ... ...

Abstract	Globally, prostate cancer (PC) is leading cause of cancer-related mortality in men worldwide. Despite significant advances in the treatment and management of this disease, the cure rates for PC remains low, largely due to late detection. PC detection is mostly reliant on prostate-specific antigen (PSA) and digital rectal examination (DRE); however, due to the low positive predictive value of current diagnostics, there is an urgent need to identify new accurate biomarkers. Recent studies support the biological role of microRNAs (miRNAs) in the initiation and progression of PC, as well as their potential as novel biomarkers for patients' diagnosis, prognosis, and disease relapse. In the advanced stages, cancer-cell-derived small extracellular vesicles (SEVs) may constitute a significant part of circulating vesicles and cause detectable changes in the plasma vesicular miRNA profile. Recent computational model for the identification of miRNA biomarkers discussed. In addition, accumulating evidence indicates that miRNAs can be utilized to target PC cells. In this article, the current understanding of the role of microRNAs and exosomes in the pathogenesis and their significance in PC prognosis, early diagnosis, chemoresistance, and treatment are reviewed.
MeSH term(s)	Male ; Humans ; MicroRNAs/genetics ; Biomarkers, Tumor/genetics ; Early Detection of Cancer ; Neoplasm Recurrence, Local ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/therapy ; Prognosis
Chemical Substances	MicroRNAs ; Biomarkers, Tumor
Language	English
Publishing date	2023-06-13
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	391889-0
ISSN	1618-0631 ; 0344-0338
ISSN (online)	1618-0631
ISSN	0344-0338
DOI	10.1016/j.prp.2023.154618
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud III Zs.20: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme.

Afshari, Amir R / Motamed-Sanaye, Ali / Sabri, Hamed / Soltani, Arash / Karkon-Shayan, Sepideh / Radvar, Sarvin / Javid, Hossein / Mollazadeh, Hamid / Sathyapalan, Thozhukat / Sahebkar, Amirhossein

Current medicinal chemistry

2021 Volume 28, Issue 24, Page(s) 4877–4892

Abstract: The current standard of care in glioblastoma multiforme (GBM), as the most morbid brain tumor, is not adequate, despite substantial progress in cancer therapy. Among patients receiving current standard treatments, including surgery, irradiation, and ... ...

Abstract	The current standard of care in glioblastoma multiforme (GBM), as the most morbid brain tumor, is not adequate, despite substantial progress in cancer therapy. Among patients receiving current standard treatments, including surgery, irradiation, and chemotherapy, the overall survival (OS) period with GBM is less than one year. The high mortality frequency of GBM is due to its aggressive nature, including accelerated growth, deregulated apoptosis, and invasion into surrounding tissues. The understanding of the molecular pathogenesis of GBM is, therefore, crucial for identifying, designing, and repurposing potential agents in future therapeutic approaches. In recent decades, it has been apparent that several neurotransmitters, specifically substance P (SP), an undecapeptide in the family of neuropeptides tachykinins, are found in astrocytes. After binding to the neurokinin-1 receptor (NK-1R), the SP controls cancer cell growth, exerts antiapoptotic impacts, stimulates cell invasion/metastasis, and activates vascularization. Since SP/NK-1R signaling pathway is a growth driver in many cancers, this potential mechanism is proposed as an additional target for treating GBM. Following an evaluation of the function of both SP and its NK-1R inhibitors in neoplastic cells, we recommend a unique and promising approach for the treatment of patients with GBM.
MeSH term(s)	Apoptosis ; Glioblastoma/drug therapy ; Humans ; Neurokinin-1 Receptor Antagonists/therapeutic use ; Receptors, Neurokinin-1 ; Substance P
Chemical Substances	Neurokinin-1 Receptor Antagonists ; Receptors, Neurokinin-1 ; Substance P (33507-63-0)
Language	English
Publishing date	2021-02-10
Publishing country	United Arab Emirates
Document type	Journal Article
ZDB-ID	1319315-6
ISSN	1875-533X ; 0929-8673
ISSN (online)	1875-533X
ISSN	0929-8673
DOI	10.2174/0929867328666210113165805
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4432: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Your last searches

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito